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Pheochromocytoma: A Frequent Indicator for MEN 2 
Claude Calmettes,* Myriam Rosenberg-Gourgin,^  Jean Caron,* and Nicole Feingold* 
Pheochromocytoma is a frequent indicator of multiple endocrine neoplasia type 2A (MEN 2A): in the 
35 French MEN 2 A families in which a pheochromocytoma occurred first in some affected members, 
30% of the patients had a pheochromocytoma as the first manifestation constituting 45% of all 
patients with pheochromocytomas. The finding of a pheochromocytoma is a strong indication for a 
search for medullary thyroid carcinoma andfor initiating family screening. (Henry Ford Hosp MedJ 
1992:40:276-7) 
Pheochromocytoma is frequently asymptomatically associ-ated with medullary thyroid carcinoma (MTC) in multiple 
endocrine neoplasia type 2 (MEN 2), Its clinical manifestations 
are usually subtle as more than 50% of patients are asympto-
matic and normotensive (1,2). Using data of the Groupe d'Etude 
des Tumeurs a Calcitonine (GETC), French Medullary Study 
Group, we have evaluated the importance of pheochromocy-
toma presenting as the initial feature of MEN 2. 
Material 
At present, the GETC lists 113 families with hereditary MEN 
2 and 66 apparently sporadic cases. Cases of pheochromocy-
toma were reported in 62 MEN 2A and in seven MEN 2B fami-
ties. From the 62 MEN 2A families, seven have been excluded 
from this study because of lack of data. Sixty-six MEN 2 cases 
(33 MEN 2A and 33 MEN 2B) have been classified as appar-
ently sporadic because no other cases had yet been found in their 
families. A pheochromocytoma was present in 28 of these 33 
sporadic MEN 2A patients and in 14 of 33 MEN 2B patients. 
For patients presenting initially with a pheochromocytoma, the 
MTC diagnosis was made either concomitantly or subsequently 
(in five cases the diagnosis was made only by a stimulated calci-
tonin [CT] procedure). 
Data 
Incidence of pheochromocytomas as an initial presentation 
Pheochromocytoma was the first manifestation in 35 of the 
55 selected MEN 2A families (Table 1) (26 index cases and 19 
relatives out of 99 MEN patients). The 20 other families without 
pheochromocytoma presenting first include 41 patients with 
pheochromocytomas. Among index cases, MTC was detected 
either clinically or biologically at the same time as or later than 
the pheochromocytoma, or by anamnesis of a patient with thy-
roid tumor. 
The relatives who had pheochromocytoma(s) as first mani-
festations had already undergone adrenal surgery and were dis-
covered by anamnesis of the index case during family screen-
ing; only a few had been tested for MTC after discovery of the 
pheochromocytoma. Pheochromocytoma was diagnosed either 
at the same time as the MTC or subsequently but never during 
the famdy screening for new cases. 
In MEN 2B families, no patients were observed with pheo-
chromocytoma as the initial presenting condition. In apparently 
sporadic MEN 2, 62% of the MEN 2A cases and 21% of the 
MEN 2B cases had pheochromocytoma as the initial manifesta-
tion. Table 2 shows the age at diagnosis of index ca.ses in MEN 
2A families and of apparently .sporadic MEN 2A cases. 
Discussion 
In comparing all MEN 2A families, the proportion of pheo-
chromocytomas is significantly higher in those families in 
which a pheochromocytoma was the initial manifestation in 
some member (64% versus 47%, P < 0.01). 
A pheochromocytoma occurring as the initial manifestation 
appears to be a relatively frequent feature of MEN 2A; in the 35 
MEN 2A families in which a pheochromocytoma occurred first 
in some affected member, 30% of the patients had a pheochro-
mocytoma as the first manifestation, constituting 45% ofall pa-
tients with pheochromocytomas. In apparently sporadic MEN 
2A, 52% of the patients had pheochromocytomas occurring as 
the first manifestation. 
A pheochromocytoma occurring first is rare in MEN 2B: no 
cases were observed in the MEN 2B families and in only one-
fourth of the apparently sporadic MEN 2B cases did this occur. 
This is likely related to the ease of early diagnosis of MTC. Pheo-
chromocytoma may occur in less aggressive diseases: the age of 
diagnosis in cases involving pheochromocytoma is older than 
the age of cases without it (20.5 versus (4.5 years, and age at 
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Table 1 
Number of Pheochromocytomas as the Initial 
Presenting Tumors in MEN 2A Families 
Table 2 
Mean Age at Diagnosis for Index MEN 2A Cases 
Families With Families Without 
Pheochromocytomas Pheochromocytomas 
First (n = 35) First (n = 20) 
Pheochromocytomas I st 45 0 
Total number of 
pheochromocytomas 99 41 
Total patients 156 88 
death 32.2 versus 19.3 years). The four patients with pheochro-
mocytoma as the first manifestation were 16, 20, 24, and 26 
years old at diagnosis. However, the age of discovery of pheo-
chromocytoma is younger in MEN 2B than in MEN 2A. 
Conclusion 
The frequency of pheochromocytoma as the initial feature of 
MEN 2 must nol be ignored; even unilateral pheochromocy-
toma may be an indicator of MEN 2. The presence of pheochro-
mocytoma is an indication for the patient and the patient's rela-
tives to be studied systematically for MTC as well as to be tested 
for von Hippel-Lindau and von Recklinghausen conditions. 
The results presented here are a reflection of the evolution of 
improved screening procedures available during the past years. 
The practice of MTC detection when pheochromocytoma oc-
curs and of pheochromocytoma detection when MTC occurs, 
using accurate means of diagnosis and family screening, will 




MEN 2A Families 
Age at Diagnosis 
Apparently 
Sporadic MEN 2A 
Age at Diagnosis 
Pheochromocytoma 1st 
MTC Ist, pheochromocytoma 2nd 
Without pheochromocytoma 
42 yrs (n = 26) 
32 yrs (n= 18) 
43yrs(n= 11) 
44 yrs (n= 15) 
33 yrs (n= 13) 
33 yrs (n=l ) 
Pheochromocytoma is quite variably expressed in MEN 2A 
families and even in different branches of the same family. The 
factors responsible for this variable expressivity remain to be 
clarified. 
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